Introduction {#Sec1}
============

The coronavirus disease (COVID-19) pandemic has had a profound impact on cancer care across the globe. Early data indicate increased risk of COVID-19 morbidity and mortality for cancer survivors \[[@CR1], [@CR2]\]. Healthcare systems have demonstrated considerable variation in preparedness and capacity, as well as organizational structure and agility in responding to disruptions in cancer treatment \[[@CR1], [@CR3]\]. Emerging guidelines for cancer care during the pandemic are working to address the increased demand on medical resources and balance the risk of treatment delays against the potential exposure to the virus \[[@CR4], [@CR5]\]. Many of these guidelines are based largely on clinical criteria and may not take into account the many factors that affect cancer outcomes, including the healthcare system factors outlined above, as well as factors such as social determinants of health and health inequities which have been exacerbated by the pandemic \[[@CR6]--[@CR8]\].

Delays in chronic disease care and treatment during a time of disaster have been well documented \[[@CR9]--[@CR12]\]. Disaster preparedness planning frequently focuses on the medical needs of those immediately affected by the disaster, with limited attention to the allocation of scarce healthcare resources for chronic disease management. However, interruptions in care due to disasters often result in increased rates of disease progression, pain, and excess mortality \[[@CR13]--[@CR15]\]. A recent study estimates 33,890 excess deaths among US cancer survivors over the age of 40 as a result of COVID-19 \[[@CR16]\].

This investigation of the impact of the pandemic on breast cancer care in the US is intended to inform the allocation of healthcare resources and services during the recovery from the current COVID-19 pandemic, and support improved preparedness for disruptions due to future disasters. This national survey of breast cancer survivors examines multiple factors that contribute to disparities in access to cancer care to gain a comprehensive understanding of delays in breast cancer care during the early period of the pandemic.

Methods {#Sec2}
=======

We developed a 50-item survey to assess the impact of COVID-19 on breast cancer care. The survey was reviewed and piloted by two breast cancer survivors and one clinician. Data were collected using Research electronic data capture (REDCap) hosted at the University of Illinois at Chicago \[[@CR17]\]. We employed the National Cancer Institute definition of cancer survivor, which considers a person to be a survivor from the time of diagnosis until the end of life \[[@CR18]\]. We used snowball sampling to recruit adult (\> 18 years old) breast cancer survivors in the US. Survey invitations were distributed via social media and email to breast cancer patient support networks.

This analysis focuses on the question of whether respondents experienced delays in cancer--related care or treatment and compares the demographic and clinical characteristics of those who reported delays and those who did not report delays.

All analyses used SPSS version 26 statistical software and Excel. Descriptive statistics of counts, proportions, means and standard deviations were calculated. Inferential statistics used were logistic regression. The study was reviewed by University of Illinois at Chicago's Institutional Review Board (Protocol \#2020‐0371; Exemption Granted: 3/27/20).

Results {#Sec3}
=======

From 4/2/20 to 4/27/20, 609 respondents (1 male) completed the survey. Average age was 47.76 (*SD* = 10.86, range 22--80, *M* = 46) (see distribution in Fig. [1](#Fig1){ref-type="fig"}); average age at diagnosis was 43 (*SD* = 10.84); 46% of respondents were within 5 years of their most recent diagnosis. Respondents were racially diverse; 78% were white, 17% were black, and 3% were Asian. The majority of respondents were non-Hispanic (95%). Top three states of residence were Illinois (15%), California (9%), and Texas (8%). More than half of respondents are currently receiving cancer treatment (63%) and have employer‐sponsored health insurance (67%). Respondents receive cancer care at academic medical centers (45%), physician's offices (26%) or community hospitals (21%).Fig. 1Age distribution and descriptive statistics in sample of respondents

Forty-four percent of participants responded *Yes* to the question: *Has any aspect of your cancer care been delayed or interrupted due to the COVID-19 pandemic?* We used a binary logistic regression model to select a best predictive model of delay (dichotomous) from a pool of independent variables including categorical variables (race, cancer stage, site of care, and health insurance) as well as age (continuous). There was no significant effect for race, insurance, site of care, or cancer stage. Reports of delays in care were slightly higher among White (46%) and Asian (50%) respondents, compared to Black respondents (36%). Those with public insurance (Medicare, Medicaid) reported slightly lower rates of delay (36%) compared with respondents with employer‐sponsored health insurance (46%) or who purchased private insurance (47%). Delays based on cancer stage showed little variation: 44%, 46%, 46%, 44%, and 42% for Stages 0, 1, 2, 3, 4, respectively. The only variable which had a significant effect was age (97 (95, 99), *p* \< 0.001) with younger respondents (*M* = 45.94, *SD* = 10.31) reporting a higher incidence of delays than older respondents (*M* = 48.98, *SD* = 11.10). Characteristics of those who experienced delays compared with those who did not are presented in Table [1](#Tab1){ref-type="table"}, along with odds ratios and confidence intervals.Table 1Characteristics of respondents who experienced delays compared with those who did not (*n* = 554)Delay95% CI for Exp(β)NoYesSigExp(β)LowerUpperRaceAmerican Indian or Alaska NativeCount210.810.660.0219.40%67%33%AsianCount770.820.780.096.71%50%50%Native Hawaiian or Pacific IslanderCount210.640.480.0210.86%67%33%BlackCount66370.510.520.083.53%64%36%WhiteCount2382040.800.790.125.11%54%46%TotalCount317253%56%44%Site of careUniversity/Academic Medical CenterCount1421270.171.690.803.57%53%47%Physician\'s OfficeCount95600.751.140.522.49%61%39%Veterans affairs hospitalCount110.761.580.0830.98%50%50%Community hospitalCount69560.451.360.613.03%55%45%Cancer CenterCount24130.134.170.6626.21%65%35%TotalCount333265%56%44%InsuranceInsurance through my jobCount2151830.960.980.531.81%54%46%Private insurance that I purchase on my ownCount20180.881.070.442.58%53%47%Public insurance (Medicaid, Medicare)Count57320.701.160.542.51%64%36%NoneCount43NANANANA%57%43%OtherCount35280.791.340.1512.04%56%44%TotalCount331264%56%44%Current cancer stageStage 0Count23180.361.800.516.36%56%44%Stage 1Count81680.202.100.676.59%54%46%Stage 2Count95820.202.120.686.61%54%46%Stage 3Count46360.361.750.535.75%56%44%Stage 4Count75540.291.870.595.96%58%42%Not sure/don\'t knowCount135NANANANA%72%28%TotalCount333263%56%44%Note: Total counts may differ slightly based on missing data

Respondents reported the highest rate of delays in routine or follow-up clinic appointments (79%), surgical breast reconstruction (66%), diagnostic imaging (60%), and lab testing (50%). Respondents reported the lowest rate of delays in genetic counseling and testing (11%) and oral therapies (13%). Approximately 30% of respondents reported delays in hospital or clinic-based cancer therapies, including radiation (30%), infusion therapies (32%), and surgical tumor removal (26%). Delay counts and proportions by type of care are presented in Table [2](#Tab2){ref-type="table"}.Table 2Delay counts and proportions by type of care (*n* = 263)DelayNo\
Age (*M* = 48.98, *SD* = 11.10)Yes\
Age (*M* = 45.94, *SD* = 10.31)Routine or follow-up clinic appointmentCount51191%21%79%Lab testingCount8989%50%50%Diagnostic imaging or testingCount6089%40%60%Genetic testing or counselingCount496%89%11%Surgery---mastectomy or lumpectomyCount4215%74%26%Surgery---breast reconstructionCount2855%34%66%Surgery---oophorectomyCount168%67%33%RadiationCount3515%70%30%Infusion (e.g., chemo, immunotherapy)Count5626%68%32%Oral therapyCount11618%87%13%OtherCount1643%27%73%Note: Respondents could choose as many categories as applicable

Discussion {#Sec4}
==========

The results of our study indicate that in the early weeks of the COVID-19 pandemic, nearly half of all breast cancer survivors experienced delays in cancer care. The data suggest that despite documented disparities in breast cancer outcomes and access to care based on factors such as race, insurance, site of care, and geography \[[@CR19], [@CR20]\], the pandemic response resulted in widespread barriers to breast cancer care regardless of other pre-existing healthcare system inequities. The consistency of delays across multiple factors also suggests that delays are not based on a strategic approach of risk-stratification in which we would expect to see higher rates of delays among patients with significant risk factors, for example, among patients who are immunocompromised or those with metastatic disease. The emerging literature points instead to ad hoc or reactive work-arounds that tried to balance shortages in medical resources and cancer survivors' risks of infection or disease progression \[[@CR21], [@CR22]\].

Significant disparities in treatment delays by age may be, in part, the result of delays in procedures or protocols specific to young women, particularly ovarian suppression. Some participants also reported delays in injections for ovarian suppression due to clinic closures or consolidation of clinical services in a different location, while others reported changes in their treatment protocol, including longer times between injections or an alternative therapy (e.g. tamoxifen) that did not require a clinic visit. These factors do not, however, explain all of the disparity in delays by age. The disparity is noteworthy for two reasons, and suggests an opportunity for further investigation. First, approximately 11% of individuals diagnosed with breast cancer in the US are under 45 years old \[[@CR23], [@CR24]\]. This population experiences more aggressive disease and higher rates of mortality. Second, data from the pandemic indicate that older people have a higher risk of mortality from COVID-19, with increased risk due to exposure during hospital or clinic-based treatment, as well as additional comorbidities. Despite these factors, our data suggest that older breast cancer survivors experienced significantly lower rates of delays in cancer treatment, with younger survivors bearing a disproportionate burden of treatment delays.

Our study results point to the pervasive impact of COVID-19 on cancer care, and a critical gap in disaster preparedness that leaves vulnerable cancer survivors at even greater risk for poor cancer outcomes, including not only clinical outcomes, but factors such as mental health, pain, and quality of life. As strategies emerge to address the backlog of patients whose care has been delayed, it is critical to recognize the differential impact of delays across the healthcare system, evidenced in part in the documented disparities in both breast cancer and COVID-19 mortality \[[@CR25]\]. The factors underlying these disparities must be recognized and addressed in the development of systems and processes to deliver high quality cancer care to those whose care has been delayed to reduce the risk of exacerbating existing health inequities \[[@CR15], [@CR26]\] and ensure access to high quality cancer care for all breast cancer survivors.

Our study has several limitations. Due to the unprecedented circumstances of a global pandemic, no validated survey exists. Given the urgency of collecting real-time data, we were not able to validate this survey before distributing. Our national sample did not permit analysis of geographic differences based on rates of COVID-19 cases and the potential impact on cancer care in regions with higher rates of infection. Recruitment through social media may not be representative of all breast cancer survivors and may result in a selection bias with a higher response rate by younger survivors. This may also be a strength as it captured a segment of the cancer survivor population that is often underrepresented.
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